US FDA warns co-administration of remdesivir and chloroquine phosphate or hydroxychloroquine sulfate may result in reduced antiviral activity of remdesivir

This potential drug interaction is based on a recently completed non-clinical laboratory study. The FDA is not aware of instances of this reduced activity occurring in the clinical setting but is continuing to evaluate all data related to remdesivir.


US Food and Drug Administration